Tuesday, Oct 17, 2023 · SEC filings
What the smart money revealed on Oct 17
415 insider filings came in. We hid 48 planned (10b5-1) sellers and 300 people whose filings were routine, like grants and tax withholding.
Cerevel Therapeutics (CERE) Director Joseph Edelman bought $20M
876,808 shares on the open market. Not a grant or an option exercise.
Lamb Weston (LW) Director William Jurgensen bought $253K
3,000 shares on the open market. Not a grant or an option exercise. Their past buys: 0 of 3 checked quarters beat the typical stock 6 months later.
Journey Medical (DERM) Director Justin Smith bought $98.3K
33,000 shares on the open market. Not a grant or an option exercise.
Byrna Technologies (BYRN) President and CEO Bryan Ganz bought $54.1K
17,000 shares on the open market. Not a grant or an option exercise.
TD SYNNEX (SNX) Director Matthew Miau sold $80.2M
Not marked as a planned 10b5-1 sale. Sold 13% of the shares they held directly. Still holds 5.81M shares.
TransDigm Group (TDG) Co-COO Joel Reiss sold $2.59M
Not marked as a planned 10b5-1 sale. Most of the shares sold came from stock options they exercised the same day. Still holds 3,600 shares directly.
G III Apparel Group (GIII) Director Laura Pomerantz sold $264K
Not marked as a planned 10b5-1 sale. Sold 35% of the shares they held directly. Still holds 20,166 shares.
Show 13 more real buys
Show 33 more real sales
13F season
Holdings as of Sep 30, 2023 are due Nov 14
40 funds have filed so far. 40 filed for the quarter before.
Biggest real insider buys, Oct 11–17
Open-market buys by officers and directors, filed in the 7 days up to Oct 17.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.